Abstract: The present disclosure provides pharmaceutical compositions for oral administration of fospropofol, or pharmaceutically acceptable salts of fospropofol, as well as methods of oral administration of fospropofol.
Abstract: The invention includes methods and compositions for treating a metabolic disorder, such as metabolic syndrome, hyperlipidemia and associated disorders, such as obesity and diabetes. The invention includes a method of treating a human subject comprising administering 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) to the subject. Further provided is the use of 12,13-diHOME as a biomarker for identifying brown adipose tissue (BAT) activation in human subjects.
Abstract: The present invention relates to oxaloacetic acid preparations and the use of hygroscopic components to prevent decomposition of the oxaloacetic acid. These compounds can then be made into sublingual lozenges and buccal lozenges to serve as nutritional supplements, medical foods or drugs. These compounds can also be used in the manufacture of oxaloacetic acid preparations in transdermal patches, inhalation preparations and anal or vaginal suppositories. Also provided are simple inexpensive tests to monitor the decomposition of oxaloacetic acid in compositions.
Abstract: A glaucocalyxin A derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof and uses thereof in the preparation of drugs for treating psoriasis.
Abstract: This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent.
Abstract: Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.
Type:
Grant
Filed:
January 6, 2020
Date of Patent:
August 2, 2022
Assignee:
AKER BIOMARINE ANTARCTIC AS
Inventors:
Inge Bruheim, Mikko Griinari, Sebastiano Banni, Per Christian Saebo, Erik Fuglseth
Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Abstract: Chemical compounds that are useful as inhibitors of mechanotransduction in the treatment of pain and modulation of touch perception and topical administration of the compounds described herein in the treatment of pain and modulation of touch perception.
Type:
Grant
Filed:
December 7, 2017
Date of Patent:
July 12, 2022
Assignee:
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
Inventors:
Gary Richard Lewin, Kathryn Anne Poole, Christiane Wetzel, Liudmila Lapatsina
Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
June 28, 2022
Assignee:
Purdue Research Foundation
Inventors:
Philip Stewart Low, Sumith A. Kularatne
Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
Type:
Grant
Filed:
February 19, 2021
Date of Patent:
June 28, 2022
Assignee:
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Inventors:
Eric Holmes, Gary Ostrander, Geoffrey Stuart Dow
Abstract: Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
Type:
Grant
Filed:
July 2, 2019
Date of Patent:
June 21, 2022
Assignee:
G1 Therapeutics, Inc.
Inventors:
Jay C. Strum, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
Type:
Grant
Filed:
March 12, 2020
Date of Patent:
May 24, 2022
Assignee:
PAR PHARMACEUTICAL, INC.
Inventors:
Suketu Sanghvi, Vinayagam Kannan, Matthew Kenney
Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
May 24, 2022
Assignee:
ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE
Inventors:
Oscar Millet Aguilar-Galindo, Arantza Sanz Parra, Ana Laín Torre, Pedro David Urquiza Ortiz, Juan Manuel Falcón Pérez, Joaquín Castilla Castrillón, Itxaso San Juan Quintana, Ganeko Bernardo-Seisdedos
Abstract: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
May 3, 2022
Assignee:
Purdue Research Foundation
Inventors:
Philip Stewart Low, Sumith A. Kularatne
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Abstract: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Abstract: Methods of treating aggression associated with Alzheimer's Disease including administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient.
Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
March 15, 2022
Assignee:
EMORY UNIVERSITY
Inventors:
David B Guthrie, Mark A Lockwood, Dennis C. Liotta, Michael G Natchus, Donald G. Stein, Iqbal Sayeed